By Michael Susin
Alimera Sciences shares fell on Tuesday after the company said it filed a lawsuit demanding ANI Pharmaceuticals to complete their merger agreement.
Shares were down 20% to $4.40. However, shares have nearly doubled over the last three months.
The pharmaceutical company said it has filed the lawsuit in the Delaware Court of Chancery asking to require ANI Pharmaceuticals to close the merger agreement.
The company said the Alimera shareholders' approval of the deal on Sept. 4 was the last requirement for completing the merger.
ANI Pharmaceuticals wasn't immediately available to provide comments for Dow Jones Newswires.
On June 24, ANI said it was buying Alimera Sciences for $5.50 per share in cash, in a deal that valued Alimera at $381 million. The offer represented a 75% premium to its closing share price of $3.15 prior to the announcement. ANI would also repay $72.5 million of Alimera debt.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
September 10, 2024 10:02 ET (14:02 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.